Functionalized nanostructures and targeted delivery systems with a focus on plant-derived natural agents for COVID-19 therapy: A review and outlook
Source abstract
Abstract
Abstract The COVID-19 pandemic strongly stimulated research on anti-SARS-CoV-2 virus treatments. The present study reviews a nanotechnology approach to this task, i.e. , in other terms, a nanomedicine approach. Nanotechnology aims to create nanostructures or nanoparticles, also called nanoformulations, for targeted delivery of drugs, as well as improved drug release control. This approach is particularly promising to enhance the antiviral effect of natural pro-drugs. Here, we review several nanoformulations developed for the targeted delivery of medications against SARS-CoV-2. We draw special attention to repurposing strategies for known antiviral and natural therapies. Also, functionalized nanoparticles with specific targeting moieties and functional groups were discussed. The summary could motivate researchers to pursue more studies in this exciting area by seeking nanotechnology-based, cutting-edge, tailored delivery strategies for the SARS-CoV-2 virus.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Advanced Drug Delivery Systems · SARS-CoV-2 and COVID-19 Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering, Chungbuk National University , Cheongju , Chungbuk, 28644 , Republic of Korea
Medicinal and Aromatic Plants Research Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre (NRC), 33 El-Behouth Street, Dokki , Giza , 12622 , Egypt
Laboratory of Nanostructures and Nanomedicine, Institute of High Pressure Physics, Polish Academy of Sciences , Sokolowska 29/37, 01-142 , Warsaw , Poland
References (100+)
Show source-provided references
1. Mehendale R, Joshi M, Patravale VB. Nanomedicines for treatment of viral diseases. Crit Rev Ther Drug Carr Syst. 2013;30:1–49.10.1615/CritRevTherDrugCarrierSyst.2013005469 ↗
2. Mourya DT, Yadav PD, Ullas PT, Bhardwaj SD, Sahay RR, Chadha MS, et al. Emerging/re-emerging viral diseases & new viruses on the Indian horizon. Indian J Med Res. 2019;149:447–67.10.4103/ijmr.IJMR_1239_18 ↗
3. Lindahl JF, Grace D. The consequences of human actions on risks for infectious diseases: a review. Infect Ecol Epidemiol. 2015;5:30048.10.3402/iee.v5.30048 ↗
4. Gunathilake T, Ching YC, Uyama H, Chuah CH. Nanotherapeutics for treating coronavirus diseases. J Drug Deliv Sci Technol. 2021;64:102634.10.1016/j.jddst.2021.102634 ↗
5. Breitbart M, Rohwer F. Here a virus, there a virus, everywhere the same virus? Trends Microbiol. 2005;13:278–84.10.1016/j.tim.2005.04.003 ↗
6. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85–164.10.1016/B978-0-12-385885-6.00009-2 ↗
7. Pal M. Severe acute respiratory syndrome: a newly recognized viral zoonosis of public health concern. Acta Sci Microbiol. 2018;1:1.10.31080/ASMI.2018.01.0008 ↗
8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.10.1016/S0140-6736(20)30251-8 ↗
9. Bauerfeind R, Von Graevenitz A, Kimmig P, Schiefer HG, Schwarz T, Slenczka W, et al. Zoonoses: Infectious diseases transmissible from animals to humans. Washington, DC: ASM Press; 2016.10.1128/9781555819262 ↗
10. Abdelrahman Z, Li M, Wang X. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses. Front Immunol. 2020;11:1–14.10.3389/fimmu.2020.552909 ↗
11. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386:995–1007.10.1016/S0140-6736(15)60454-8 ↗
12. The Lancet. Emerging understandings of 2019-nCoV. Lancet. 2020;395:311.10.1016/S0140-6736(20)30186-0 ↗
13. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing; LLC. 2022.
14. US Food and Drug Administration. COVID-19 update: FDA broadens emergency use authorization for Veklury (remdesivir) to include all hospitalized patients for treatment of COVID-19. 2020.
15. Rakhsha A, Azghandi S, Taghizadeh-Hesary F. Decision on chemotherapy amidst COVID-19 pandemic: a review and a practical approach from Iran. Infect Chemother. 2020;52:496–502.10.3947/ic.2020.52.4.496 ↗
16. Fadavi P, Houshyari M, Yousefi Kashi AS, Jarrahi AM, Roshanmehr F, Broomand MA, et al. Review on the oncology practice in the midst of COVID-19 crisis: the challenges and solutions. Asian Pac J Cancer Prev. 2021;22:19–24.10.31557/APJCP.2021.22.1.19 ↗
17. Vecitis CD. Antiviral-nanoparticle interactions and reactions. Environ Sci: Nano. 2021;8:11–9.10.1039/D0EN00980F ↗
18. Yang KC, Lin JC, Tsai HH, Hsu CY, Shih V, Hu CJ. Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control. Drug Deliv Transl Res. 2021;11:1420–37.10.1007/s13346-021-00965-y ↗
19. He H. Vaccines and antiviral agents. Curr Issues Mol Virol: Viral Genet Biotechnol Appl. 2013;2013:239–50.10.5772/56866 ↗
20. Saha RP, Sharma AR, Singh MK, Samanta S, Bhakta S, Mandal S, et al. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Front Pharmacol. 2020;11:1258.10.3389/fphar.2020.01258 ↗
21. Deb B, Shah H, Goel S. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. J Biosci. 2020;45:1–10.10.1007/s12038-020-00053-2 ↗
22. Saxena A. Drug targets for COVID-19 therapeutics: Ongoing global efforts. J Biosci. 2020;45:87.10.1007/s12038-020-00067-w ↗
23. Liz-Marzán LM, Nel AE, Brinker CJ, Chan WCW, Chen C, Chen X, et al. What do we mean when we say nanomedicine? ACS Nano. 2022;16:13257–9.10.1021/acsnano.2c08675 ↗
24. Doyle DJ. Nanotechnology in anesthesia and medicine. Adv Anesth. 2013;31:181–200.10.1016/j.aan.2013.08.010 ↗
25. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101–24.10.1038/s41573-020-0090-8 ↗
26. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine. 2016;11:673–92.10.2217/nnm.16.5 ↗
27. Paul S, Mukherjee S, Banerjee P. Recent advancement in nanomaterial-encapsulated drug delivery vehicles for combating cancer, COVID-19, and HIV-like chronic diseases. Mater Adv. 2023;4:2042–61.10.1039/D2MA01075E ↗
28. Rai M, Bonde S, Yadav A, Bhowmik A, Rathod S, Ingle P, et al. Nanotechnology as a shield against COVID-19: current advancement and limitations. Viruses. 2021;13:1–17.10.3390/v13071224 ↗
29. Mishra R, Chaudhary K, Mishra I. Weapons and strategies against COVID-19: a perspective. Curr Pharm Biotechnol. 2024;25:144–58.10.2174/1389201024666230525161432 ↗
30. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13.10.3389/fcimb.2013.00013 ↗
31. Ayan S, Aranci-Ciftci K, Ciftci F, Ustundag CB. Nanotechnology and COVID-19: prevention, diagnosis, vaccine, and treatment strategies. Front Mater. 2023;9:1–19.10.3389/fmats.2022.1059184 ↗
32. Vazquez-Munoz R, Lopez-Ribot JL. Nanotechnology as an alternative to reduce the spread of COVID-19. Challenges. 2020;11:1–14. 10.3390/challe11020015.10.20944/preprints202006.0301.v1 ↗
33. Yayehrad AT, Siraj EA, Wondie GB, Alemie AA, Derseh MT, Ambaye AS. Could nanotechnology help to end the fight against COVID-19? Review of current findings, challenges and future perspectives. Int J Nanomed. 2021;16:5713–43.10.2147/IJN.S327334 ↗
34. Varahachalam SP, Lahooti B, Chamaneh M, Bagchi S, Chhibber T, Morris K, et al. Nanomedicine for the SARS-CoV-2: state-of-the-art and future prospects. Int J Nanomed. 2021;16:539–60.10.2147/IJN.S283686 ↗
35. Chowdhury NK, Deepika, Choudhury R, Sonawane GA, Mavinamar S, Lyu X, et al. Nanoparticles as an effective drug delivery system in COVID-19. Biomed Pharmacother. 2021;143:112162.10.1016/j.biopha.2021.112162 ↗
36. Xi Y, Ma R, Li S, Liu G, Liu C. Functionally designed nanovaccines against SARS-CoV-2 and its variants. Vaccines. 2024;12:1–18. 10.3390/vaccines12070764.10.3390/vaccines12070764 ↗
37. Skwarek A, Gąsecka A, Jaguszewski MJ, Szarpak Ł, Dzieciątkowski T, Filipiak KJ. Nanoparticles: a breakthrough in COVID-19 prevention, diagnosis and treatment. Arch Med Sci. 2023;19:1410–20.10.5114/aoms/142103 ↗
38. Chintapula U, Karim S-U, Iyer PR, Asokan-Sheeja H, Neupane B, Nazneen F, et al. A novel nanocomposite drug delivery system for SARS-CoV-2 infections. Nanoscale Adv. 2024;6:3747–58.10.1039/D4NA00361F ↗
39. Huang X, Kon E, Han X, Zhang X, Kong N, Mitchell MJ, et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat Nanotechnol. 2022;17:1027–37.10.1038/s41565-022-01174-5 ↗
40. Katoch P, Raina K, Sharma R, Sharma R, Chaudhary A. Ayush Kwath: A major contribution of Ayurveda in preventing COVID-19 infection. Curr Drug Ther. 2024;19:60–80.10.2174/1574885518666230601150338 ↗
41. Rauf A, Abu-Izneid T, Khalil AA, Hafeez N, Olatunde A, Rahman M, et al. Nanoparticles in clinical trials of COVID-19: an update. Int J Surg. 2022;104:106818.10.1016/j.ijsu.2022.106818 ↗
42. Li Z, Zhao T, Li J, Yu Q, Feng Y, Xie Y, et al. Nanomedicine based on natural products: improving clinical application potential. J Nanomaterials. 2022;2022:3066613.10.1155/2022/3066613 ↗
43. Liao W, Li Y, Wang J, Zhao M, Chen N, Zheng Q, et al. Natural products-based nanoformulations: a new approach targeting CSCs to cancer therapy. Int J Nanomed. 2022;17:4163–93.10.2147/IJN.S380697 ↗
44. Khare T, Palakurthi SS, Shah BM, Palakurthi S, Khare S. Natural product-based nanomedicine in treatment of inflammatory bowel disease. Int J Mol Sci. 2020;21:1–22. 10.3390/ijms21113956.10.3390/ijms21113956 ↗
45. Delshadi R, Bahrami A, McClements DJ, Moore MD, Williams L. Development of nanoparticle-delivery systems for antiviral agents: A review. J Control Release. 2021;331:30–4.10.1016/j.jconrel.2021.01.017 ↗
46. Horcajada P, Serre C, Vallet-Regí M, Sebban M, Taulelle F, Férey G. Metal–organic frameworks as efficient materials for drug delivery. Angew Chem Int Ed. 2006;45:5974–78.10.1002/anie.200601878 ↗
47. Pradhan D, Biswasroy P, Goyal A, Ghosh G, Rath G. Recent advancement in nanotechnology-based drug delivery system against viral infections. AAPS PharmSciTech. 2021;22:47.10.1208/s12249-020-01908-5 ↗
48. Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv. 2018;15:93–114.10.1080/17425247.2017.1360863 ↗
49. Alipour S, Mahmoudi L, Ahmadi F. Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19. Drug Deliv Transl Res. 2023;13:705–15.10.1007/s13346-022-01251-1 ↗
50. Wang F-Y, Chen Y, Huang Y-Y, Cheng C-M. Transdermal drug delivery systems for fighting common viral infectious diseases. Drug Deliv Transl Res. 2021;11:1498–508.10.1007/s13346-021-01004-6 ↗
51. Limenh LW. Advances in the transdermal delivery of antiretroviral drugs. SAGE Open Med. 2024;12:20503121231223600.10.1177/20503121231223600 ↗
52. Gabai A, Zeppieri M, Finocchio L, Salati C. Innovative strategies for drug delivery to the ocular posterior segment. Pharmaceutics. 2023;15:1–38.10.3390/pharmaceutics15071862 ↗
53. Li S, Chen L, Fu Y. Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. J Nanobiotechnol. 2023;21:232.10.1186/s12951-023-01992-2 ↗
54. Žigrayová D, Mikušová V, Mikuš P. Advances in antiviral delivery systems and chitosan-based polymeric and nanoparticulate antivirals and antiviral carriers. Viruses. 2023;15:1–56.10.3390/v15030647 ↗
55. Bhatti A, DeLong RK. Nanoscale interaction mechanisms of antiviral activity. ACS Pharmacol Transl Sci. 2023;6:220–28.10.1021/acsptsci.2c00195 ↗
56. Yasamineh S, Kalajahi HG, Yasamineh P, Yazdani Y, Gholizadeh O, Tabatabaie R, et al. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. J Nanobiotechnol. 2022;20:440.10.1186/s12951-022-01625-0 ↗
57. Rodrigues ICP, Campo KN, Arns CW, Gabriel LP, Webster TJ, Lopes ÉSN. From bulk to nanoparticles: an overview of antiviral materials, its mechanisms, and applications. Part Part Syst Charact. 2021;38:2100044.10.1002/ppsc.202100044 ↗
58. Sanna V, Satta S, Hsiai T, Sechi M. Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition. Eur J Med Chem. 2022;231:114121.10.1016/j.ejmech.2022.114121 ↗
59. Cojocaru F-D, Botezat D, Gardikiotis I, Uritu C-M, Dodi G, Trandafir L, et al. Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics. 2020;12:1–34. 10.3390/pharmaceutics12020171.10.3390/pharmaceutics12020171 ↗
60. Maginnis MS. Virus-receptor interactions: The key to cellular invasion. J Mol Biol. 2018;430:2590–611.10.1016/j.jmb.2018.06.024 ↗
61. Tulbah AS, Lee W-H. Physicochemical characteristics and in vitro toxicity/anti-SARS-CoV-2 activity of favipiravir solid lipid nanoparticles (SLNs). Pharmaceuticals. 2021;14:1–14. 10.3390/ph14101059.10.3390/ph14101059 ↗
62. AbouAitah K, Allayh AK, Wojnarowicz J, Shaker YM, Swiderska-Sroda A, Lojkowski W. Nanoformulation composed of rllagic acid and functionalized zinc oxide nanoparticles inactivates DNA and RNA viruses. Pharmaceutics. 2021;13:1–18.10.3390/pharmaceutics13122174 ↗
63. Bauer AN, Williams JF, Pokhrel LR, Garcia S, Majumdar N, Eells JB, et al. Evaluating molecular mechanism of viral inhibition of aerosolized smart nano-enabled antiviral therapeutic (SNAT) on SARS-CoV-2-Infected hamsters. Toxics. 2024;12:1–18. 10.3390/toxics12070495.10.3390/toxics12070495 ↗
64. Wang H, Luo S, Xie M, Chen Z, Zhang Y, Xie Z, et al. ACE2 receptor-targeted inhaled nanoemulsions inhibit SARS-CoV-2 and attenuate inflammatory responses. Adv Mater. 2024;36:2311537.10.1002/adma.202311537 ↗
65. Elimam H, El-Sawy HS, Fayed MAA, Mahmoud SH, Bakr RO, Saleh RM, et al. Antiviral potential of rosuvastatin and hesperidin in combination with favipiravir liposomal nanoformulations in targeting the main protease (Mpro) of SARS-CoV-2: molecular docking, molecular dynamics and in-vitro studies. J Drug Deliv Sci Technol. 2024;97:105799.10.1016/j.jddst.2024.105799 ↗
66. Guareschi F, Del Favero E, Ricci C, Cantù L, Brandolini M, Sambri V, et al. Cyclosporine a micellar nasal spray characterization and antiviral action against SARS-CoV-2. Eur J Pharm Sci. 2024;193:106673.10.1016/j.ejps.2023.106673 ↗
67. de M, Ribeiro LN, Fonseca BB. The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic. Future Microbiol. 2020;15:1571–82.10.2217/fmb-2020-0118 ↗
68. Tai TT, Wu TJ, Wu HD, Tsai YC, Wang HT, Wang AM, et al. A strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine: a preclinical pharmacokinetic study. Clin Transl Sci. 2021;14:132–6.10.1111/cts.12923 ↗
69. Yang D. Application of nanotechnology in the COVID-19 pandemic. Int J Nanomed. 2021;16:623–49.10.2147/IJN.S296383 ↗
70. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm. 2007;337:1–24.10.1016/j.ijpharm.2007.03.025 ↗
71. Mascio MD. Towards COVID-19 prophylaxis: an AIDS preclinical research perspective. Cancer Stud Ther. 2020;5:1–10.
72. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.e8.10.1016/j.cell.2020.02.052 ↗
73. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620.10.1038/s41467-020-15562-9 ↗
74. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.10.1038/s41586-020-2012-7 ↗
75. Hasan A, Paray BA, Hussain A, Qadir FA, Attar F, Aziz FM, et al. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. J Biomol Struct Dyn. 2021;39:3025–33.10.1080/07391102.2020.1754293 ↗
76. Medhi R, Srinoi P, Ngo N, Tran H-V, Lee TR. Nanoparticle-based strategies to combat COVID-19. ACS Appl Nano Mater. 2020;3:8557–80.10.1021/acsanm.0c01978 ↗
77. Gil C, Ginex T, Maestro I, Nozal V, Barrado-Gil L, Cuesta-Geijo MÁ, et al. COVID-19: drug targets and potential treatments. J Med Chem. 2020;63:12359–86.10.1021/acs.jmedchem.0c00606 ↗
78. Kim C-H. Anti–SARS-CoV-2 natural products as potentially therapeutic agents. Front Pharmacol. 2021;12:1–27.10.3389/fphar.2021.590509 ↗
79. Miranda RR, Ferreira NN, Souza EE, Lins PMP, Ferreira LMB, Krüger A, et al. Modulating fingolimod (FTY720) anti-SARS-CoV-2 activity using a PLGA-based drug delivery system. ACS Appl Bio Mater. 2022;5:3371–83.10.1021/acsabm.2c00349 ↗
80. Halevas E, Mavroidi B, Kokotidou C, Moschona A, Sagnou M, Mitraki A, et al. Remdesivir-loaded bis-MPA hyperbranched dendritic nanocarriers for pulmonary delivery. J Drug Deliv Sci Technol. 2022;75:103625.10.1016/j.jddst.2022.103625 ↗
81. Ucar B, Acar T, Arayici PP, Derman S. A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2. Nanotechnology. 2021;32(48):485601.10.1088/1361-6528/ac1c22 ↗
82. Abdel-Bar HM, Abdallah IA, Fayed MAA, Moatasim Y, Mostafa A, El-Behairy MF, et al. Lipid polymer hybrid nanocarriers as a combinatory platform for different anti-SARS-CoV-2 drugs supported by computational studies. RSC Adv. 2021;11:28876–91.10.1039/D1RA04576H ↗
83. Vartak R, Patil SM, Saraswat A, Patki M, Kunda NK, Patel K. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine. 2021;16:1187–202.10.2217/nnm-2020-0475 ↗
84. Brunaugh AD, Seo H, Warnken Z, Ding L, Seo SH, Smyth HDC. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae. PLOS ONE. 2021;16:e0246803.10.1371/journal.pone.0246803 ↗
85. de Barros AO, Pinto SR, dos Reis SR, Ricci-Junior E, Alencar LM, Bellei NC, et al. Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect. J Nanostruct Chem. 2023;13:263–81.10.1007/s40097-022-00476-3 ↗
86. Surnar B, Kamran MZ, Shah AS, Dhar S. Clinically approved antiviral drug in an orally administrable nanoparticle for COVID-19. ACS Pharmacol Transl Sci. 2020;3:1371–80.10.1021/acsptsci.0c00179 ↗
87. Alhakamy NA, Ahmed OAA, Ibrahim TS, Aldawsari HM, Eljaaly K, Fahmy UA, et al. Evaluation of the antiviral activity of sitagliptin-glatiramer acetate nano-conjugates against SARS-CoV-2 virus. Pharmaceuticals. 2021;14:1–15. 10.3390/ph14030178.10.3390/ph14030178 ↗
88. Zoulikha M, Huang F, Wu Z, He W. COVID-19 inflammation and implications in drug delivery. J Control Release. 2022;346:260–74.10.1016/j.jconrel.2022.04.027 ↗
89. Gedefaw L, Ullah S, Lee TMH, Yip SP, Huang CL. Targeting inflammasome activation in COVID-19: delivery of RNA interference-based therapeutic molecules. Biomedicines. 2021;9:1–28.10.3390/biomedicines9121823 ↗
90. Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021;29:2219–26.10.1016/j.ymthe.2021.05.004 ↗
91. Mehta M, Prasher P, Sharma M, Shastri MD, Khurana N, Vyas M, et al. Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): a hypothesis. Med Hypotheses. 2020;144:110254.10.1016/j.mehy.2020.110254 ↗
92. Petcherski A, Tingley BM, Martin A, Adams S, Brownstein AJ, Steinberg RA, et al. ENDO-lysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections. bioRxiv. 2023;2023.05.08.539898.10.15252/rc.2023204414 ↗
93. McHugh KJ. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19. Bioeng Transl Med . 2020;5(2):e10163.10.1002/btm2.10163 ↗
94. Reçber T, Timur SS, Erdoğan Kablan S, Yalçın F, Karabulut TC, Neslihan Gürsoy R, et al. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. J Pharm Biomed Anal. 2022;214:114693.10.1016/j.jpba.2022.114693 ↗
95. Abdellatif AAH, Alsowinea AF. Approved and marketed nanoparticles for disease targeting and applications in COVID-19. Nanotechnol Rev. 2021;10:1941–77.10.1515/ntrev-2021-0115 ↗
96. Frank N, Dickinson D, Lovett G, Liu Y, Yu H, Cai J, et al. Evaluation of novel nasal mucoadhesive nanoformulations containing lipid-soluble EGCG for long COVID treatment. Pharmaceutics. 2024;16:1–14. 10.3390/pharmaceutics16060791.10.3390/pharmaceutics16060791 ↗
97. Al Ashmawy AZG, Balata GF. Formulation and in vitro characterization of nanoemulsions containing remdesivir or licorice extract: a potential subcutaneous injection for coronavirus treatment. Colloids Surf B: Biointerfaces. 2024;234:113703.10.1016/j.colsurfb.2023.113703 ↗
98. Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Åslund AKO, et al. Delivering the power of nanomedicine to patients today. J Control Release. 2020;326:164–71.10.1016/j.jconrel.2020.07.007 ↗
99. Ali IH, Elkashlan AM, Hammad MA, Hamdi M. Antimicrobial and anti-SARS-CoV-2 activities of smart daclatasvir-chitosan/gelatin nanoparticles-in-PLLA nanofibrous medical textiles; in vitro, and in vivo study. Int J Biol Macromol. 2023;253:127350.10.1016/j.ijbiomac.2023.127350 ↗
100. Yang H, Zhou J-N, Zhang X-M, Ling D-D, Sun Y-B, Li C-Y, et al. Nanoengineered red blood cells loaded with TMPRSS2 and cathepsin l inhibitors block SARS-CoV-2 pseudovirus entry into lung ACE2+ cells. Adv Mater. 2024;36:2310306.10.1002/adma.202310306 ↗